TOI Streamlines Oncology Admin With AI, Eyes $2 Million Annual Savings From New Automation Partnership

Automation Drives Over 80% Reduction in Admin Submission Times Across 100+ Clinics

The Oncology Institute (NASDAQ:TOI) just made a decisive leap forward in administrative efficiency. Through a co-development partnership with healthcare technology company Ascertain, TOI has rolled out an AI-driven "Unified Payer Portal"—achieving near-touchless prior authorization workflows that slash manual labor and unlock massive time savings across its operations.

New System Shows Rapid Results: 80% Faster Submission, Hundreds of Staff Hours Saved

Launched in just eight weeks from concept to early deployment, this new AI automation has already shown substantial results at pilot sites. Since its September 2025 go-live, TOI has reduced office visit authorization submission times by more than 80%. For a sprawling network that includes over 100 clinics and affiliate sites, this shift is freeing up hundreds of staff hours every week—time that now goes back to supporting direct patient care instead of repetitive admin tasks.

Technology and Partnership Fuel Speed and Scalability

TOI and Ascertain’s collaboration stands out for both speed and scalability. It took just eight weeks from the statement of work to the first live deployment—highlighting not only how nimble modern healthcare tech can be, but also how well-matched these organizations are in pursuit of operational efficiency. The automated system eliminates most of the manual steps in payer communications and documentation, and now covers all TOI clinics and affiliates for prior authorization workflows. The ultimate aim: give providers and support staff more time to focus on patient outcomes, not paperwork.

Leadership: A Step Change for Value-Based Cancer Care

Leaders at both organizations emphasize that this is just the beginning. Ascertain’s CEO, Dr. Mark Michalski, frames the partnership as a template for future touchless solutions, making administrative processes "faster, more accurate, and far less burdensome for clinical teams." For TOI CEO Daniel Virnich, the drive is operational excellence—deploying thoughtful automation to let clinicians do what matters most: serve patients. Both hint at continued joint development in the near future.

What’s Next for TOI? Focus on Patient Care, Continued Innovation

Looking ahead, TOI intends to scale this automation across additional workflows, potentially broadening savings beyond the $2 million projected for 2026. With its expansive network of clinics and a tech-driven push for value-based care, the organization appears set to deliver further operational improvements while keeping the spotlight on patients, not paperwork.

For investors and healthcare industry observers alike, TOI’s AI-powered leap offers a real-world example of technology’s role in modernizing clinical operations and unlocking new efficiencies in value-based care.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI